Israel's Betalin Therapeutics plans IPO to fund diabetes trials
JERUSALEM, Sept 16 (Reuters) - Israel's Betalin Therapeutics is preparing an initial public offering that will value the biotech firm between $150-170...
JERUSALEM, Sept 16 (Reuters) - Israel's Betalin Therapeutics is preparing an initial public offering that will value the biotech firm between $150-170...